Clinicopathological and Molecular Changes Induced by Neoadjuvant Chemotherapy and Endocrine Therapy in HR-Positive/HER2-Low and HR-Positive/HER2-0 Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer
ESMO Open 2024 Jun 28;9(7)103619, F Schettini, S Nucera, F Brasó-Maristany, I De Santo, T Pascual, M Bergamino, P Galván, B Conte, E Seguí, I García Fructuoso, R Gómez Bravo, P Rivera, AB Rodríguez, O Martínez-Sáez, S Ganau, E Sanfeliu, B González-Farre, MJ Vidal Losada, B Adamo, I Cebrecos, E Mension, G Oses, P Jares, S Vidal-Sicart, M Mollà, M Muñoz, A PratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.